-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Elevance Health, Raises Price Target to $469

Benzinga·10/07/2026 14:17:08
Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $457 to $469.